Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag + Ciclosporin A in Moderate Aplastic Anemia
NCT02773225Phase 3Completed
- Sponsor
- B. Höchsmann
- Start
- Jan 2015
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in aplastic anemia comparing Eltrombopag + CSA with Placebo + CSA (2 arms). Primary endpoint: Trilineage Hematologic Response Rate (CR + PR) at 6 months. Started Jan 2015; status: completed.
02
Drugs
eltrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT02773225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02773225.